|
TTD
Drug ID:
DAP001073
Drug
Information |
Name | Phenindamine | Synonyms | 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno- (2,1-c)pyridine; C07790; CHEBI:130096; 1H-Indeno[2,1-c]pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-; 82-88-2; D08353; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; LS-81959; 5-20-08-00420 (Beilstein Handbook Reference); 1H-Indeno(2,1-c)pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; PDSP2_000150; CHEMBL278398; NU 1504; Phenindiamine; Phenindaminum; Phenindamine; 5503-08-2 (hydrochloride); BRN 0221083; 569-59-5 (tartrate); Fenindamina; DB01619; EINECS 201-443-4; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine; Phenindamine (INN); Phenindaminum [INN-Latin]; Thephorin; PDSP1_000151; Phenindamine [INN:BAN]; L001053; Fenindamina [INN-Spanish]; AC1L1X1J; CID11291; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine | Trade Name | Nolahist; Thephorin | Company | Amarin Pharmaceuticals | Indication | Common Cold and Allergies | Approved [1] | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format | Therapeutic Class | Antihistamine | CAS Number | CAS 82-88-2 | Formular | C19H19N | PubChem Compound ID | CID 11291. | PubChem Substance ID | SID 9992. | SuperDrug ATC ID | R06AX04; | SuperDrug CAS ID | 000082882; | Target | Histamine H1 receptor |  | Antagonist | [2] | Ref 1 | Drug information of Phenindamine, 2008 To Reference | Ref 2 | The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|
|